Shares of small biotech Instil Bio TIL have surged more than six times in market value in the past week. The upside came after rival Summit Therapeutics SMMT reported encouraging data from a ...
Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin a phase 1 trial before the end of 2025. This ...
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL) (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code ...
Summit Therapeutics' trial data drove stocks up by 150% for Summit, 40% for BioNTech and 500% for Instil Bio. Jefferies upgrades Instil Bio with a $52 target, forecasting over 300% upside from the ...
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment ...
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 ...
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical ...
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC ...
If you're an investor looking for stocks that can make dramatic gains in a short amount of time, you may have noticed a small-cap biopharmaceutical company called Instil Bio (NASDAQ: TIL) has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results